Faricimab▼ for Macular Edema Due to Retinal Vein Occlusion: Rationale and Design of the Phase 3 BALATON and COMINO Trials
This presentation describes the study design of two identical, global, multicenter, randomized, double-masked, active comparator-controlled phase 3 studies of anti-VEGF treatment-naïve patients with retinal vein occlusion (RVO). The BALATON (branch RVO) and COMINO (central/hemiretinal RVO) studies compare the noninferiority of 6 one-monthly doses of faricimab▼ 6.0 mg with aflibercept 2.0 mg in mean change from baseline in BCVA (Week 24).